Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Assets (2024 - 2025)

Xilio Therapeutics' Assets history spans 2 years, with the latest figure at $133.7 million for Q3 2025.

  • For Q3 2025, Assets rose 79.08% year-over-year to $133.7 million; the TTM value through Sep 2025 reached $133.7 million, up 79.08%, while the annual FY2024 figure was $71.1 million, N/A changed from the prior year.
  • Assets for Q3 2025 was $133.7 million at Xilio Therapeutics, roughly flat from $133.8 million in the prior quarter.
  • Across five years, Assets topped out at $133.8 million in Q2 2025 and bottomed at $71.1 million in Q4 2024.